New drug cocktail aims to shrink Hard-to-Treat GI cancers
NCT ID NCT07243938
First seen Jan 06, 2026 · Last updated May 24, 2026 · Updated 23 times
Summary
This study tests a combination of two drugs (zanidatamab and tislelizumab) plus chemotherapy or radiation in people with HER2-positive gastrointestinal cancers, including rectal, stomach, and colorectal cancers. The goal is to see if this treatment can shrink tumors before surgery or control advanced disease. About 70 adults aged 18 to 75 will take part, and the study will track how many patients have a complete response and how long they live without their cancer growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.